Intravenous Recombinant Tissue-Type Plasminogen Activator [Clinical Sciences]

Conclusions—In this population, previous IVT improved functional outcome and survival at 3 months in patients treated by MT. While waiting for randomized controlled trials, this result encourages not to avoid IVT before MT.

Source: Stroke - May 25, 2018 Category: Neurology Authors: Marc Ferrigno, Nicolas Bricout, Didier Leys, Laurent Estrade, Charlotte Cordonnier, Thomas Personnic, Maeva Kyheng, Hilde Henon Tags: Cerebrovascular Disease/Stroke, Ischemic Stroke Original Contributions Source Type: research